Biotech News

CG Oncology to Present at Upcoming Investor Conferences in September

CG Oncology, Inc. (CGON)CG Oncology, Inc.Conference / presentation

CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

Cantor Fitzgerald Global Healthcare Conference Presentation Time: Wednesday, September 9, 2026 at 8:00am ET

Morgan Stanley Global Healthcare Conference Presentation Time: Monday, September 14, 2026 at 4:50pm ET

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com

Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology megan.knight@cgoncology.com

Related news

CG Oncology, Inc.

Bladder-Cancer Immunotherapy CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response. Cretostimogene Grenadenorepvec Cretostimogene has been studied across more than 600 patients with...

Recent company news

Stock data

Close
75.62 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States